Qube Research & Technologies LTD Aim Immuno Tech Inc. Transaction History
Qube Research & Technologies LTD
- $62.3 Billion
- Q2 2024
A detailed history of Qube Research & Technologies LTD transactions in Aim Immuno Tech Inc. stock. As of the latest transaction made, Qube Research & Technologies LTD holds 2 shares of AIM stock, worth $0. This represents 0.0% of its overall portfolio holdings.
Number of Shares
2
Previous 2
-0.0%
Holding current value
$0
Previous $0
NaN%
% of portfolio
0.0%
Previous 0.0%
Shares
3 transactions
Others Institutions Holding AIM
# of Institutions
39Shares Held
8.44MCall Options Held
0Put Options Held
0-
Armistice Capital, LLC New York, NY4.08MShares$1.26 Million0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.99MShares$616,4980.0% of portfolio
-
Black Rock Inc. New York, NY698KShares$216,4620.0% of portfolio
-
Geode Capital Management, LLC Boston, MA401KShares$124,3180.0% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny229KShares$70,9300.0% of portfolio
About AIM ImmunoTech Inc.
- Ticker AIM
- Exchange NYSE
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 48,049,300
- Market Cap $14.9M
- Description
- AIM ImmunoTech Inc., an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. The company's products include Ampligen, a drug of macromolecular ribonucleic acid molecules for the treatment of chronic fatigue syndrome...